General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Aria(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Edwards(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Imbria(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), VADovations(NONE) RESEARCH/RESEARCH GRANTS: Medtronic(SIGNIFICANT), GlaxoSmithKline(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Mesoblast(SIGNIFICANT), Corvia(SIGNIFICANT), Tenax(SIGNIFICANT), NIH/NHLBI(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Corvia(SIGNIFICANT), GlaxoSmithKline(SIGNIFICANT), Medtronic(SIGNIFICANT), Mesoblast(SIGNIFICANT), NIH/NHLBI(SIGNIFICANT), Tenax(SIGNIFICANT)

View Full Disclosure